AKT1 and oral mucositis: Future investigations may evaluate palifermin for targeted therapy-associated stomatitis; however, caution is warranted, as chemotherapy/radiotherapy-induced oral mucositis is better understood than the pathobiology of stomatitis associated with PI3K/mTor/AKT pathway inhibitors [35,36].